Modern clinical management of arterial hypertension fixed or free combination therapies?

High Blood Pressure and Cardiovascular Prevention

Volumn 18, Issue SUPPL. 1, 2011, Pages 3-11

  Tocci, Giuliano ^a   Volpe, Massimo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

ACE inhibitors; Amlodipine besylate; Angiotensin receptor blockers; Antihypertensive therapy; Arterial hypertension; Calcium antagonists; Combination therapy

Indexed keywords

AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; HUMAN; HYPERTENSION; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION;

EID: 80052463812     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.2165/1159615-s0-000000000-00000     Document Type: Review

References (41)

1. Turnbull F,Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-9 (Pubitemid 40973424)
2. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-35 (Pubitemid 37410190)
3. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121-3 (Pubitemid 351731743)
4. Danaei G, Finucane MM,Lin JK, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 2011; 377: 568-77
5. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur JCardiovasc Prev Rehabil 2009; 16: 121-37
6. Volpe M, Tocci G, Trimarco B, et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens 2007; 25: 1491-8 (Pubitemid 46918838)
7. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303: 2043-50
8. Bramlage P, Bohm M, Volpe M, et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens (Greenwich) 2010; 12: 666-77
9. Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008; 26: 819-24 (Pubitemid 351354932)
10. Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010; 28: 1584-90
11. Volpe M, Tocci G, Avogaro A, et al. Global cardiovascular risk assessment in different clinical settings: basal results of the EFFECTUS (Evaluation of Final Feasible Effect of Control Training and Ultra-Sensitisation) Programme. High Blood Pressure and Cardiovascular Prevention 2009; 16: 55-63
12. Tocci G, Giovannelli F, Sciarretta S, et al. Management of hypertension and stroke prevention: results of the Italian cardiologist survey. Int J Clin Pract 2009; 63: 207-16
13. Volpe M, Tocci G. Managing hypertension in cardiology practice according to risk profile. Int J Clin Pract 2008; 62: 1403-12
14. Prandin MG, Cicero AF, Veronesi M, et al. Persistence on treatment and blood pressure control with different first-line antihypertensive treatments: a prospective evaluation. Clin Exp Hypertens 2007; 29: 553-62 (Pubitemid 350223249)
15. Borghi C, Veronesi M, Dormi A, et al. Persistence of treatment and blood pressure control in elderly hypertensive patients treated with different classes of antihypertensive drugs. Am J Geriatr Cardiol 2007; 16: 280-6
16. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25: 1751-62 (Pubitemid 47356612)
17. White WB, Johnson MF, Black HR, et al. Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapy. Am J Hypertens 2001; 14: 1239-47 (Pubitemid 33151481)
18. Elliott WJ. Circadian variation in the timing of stroke onset: a meta-analysis. Stroke 1998; 29: 992-6 (Pubitemid 28228162)
19. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo- Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906 (Pubitemid 41265663)
20. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28
21. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427-32
22. Wald DS, LawM, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med 2009; 122: 290-300
23. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72 (Pubitemid 37430158)
24. Hackam DG, Khan NA, Hemmelgarn BR, et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol 2010; 26: 249-58
25. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertensionmanagement: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-58
26. Chobanian AV. Shattuck Lecture. The hypertension paradox - more uncontrolled disease despite improved therapy. N Engl JMed 2009; 361: 878-87
27. Borghi C, Cicero AF. Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/ enalapril. Clin Drug Invest 2010; 30: 843-54
28. Tocci G, Palano F, Pagannone E, et al. Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine. Expert Rev Cardiovasc Ther 2009; 7: 115-23
29. Volpe M, Brommer P, Haag U, et al. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Invest 2009; 29: 11-25
30. Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin Drug Invest 2009; 29: 381-91
31. Oparil S, Melino M, Lee J, et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010; 32: 1252-69
32. de Luca N, Mallion JM, O'RourkeMF, et al. Regression of left ventricularmass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004; 17: 660-7 (Pubitemid 39091546)
33. Morisco C, Lembo G, Sarno D, et al. Benefits of combination therapy in hypertensive patients with associated coronary artery disease: a subgroup with specific demands. J Cardiovasc Pharmacol 1998; 31 (Suppl. 2): S27-33 (Pubitemid 128700006)
34. Volpe M, Tocci G, Pagannone E. Fewer mega-trials and more clinically oriented studies in hypertension research? The case of blocking the renin-angiotensinaldosterone system. J Am Soc Nephrol 2006; 17 (4 Suppl. 2): S36-43
35. Volpe M, Tocci G. Therapeutic implications of recent megatrials in hypertension: in favor of new drugs. J Nephrol 2007; 20 (Suppl. 12): S12-8 (Pubitemid 351266132)
36. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399-407
37. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97
38. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003 (Pubitemid 34286536)
39. Raccomandazioni AIFA per la terapia di combinazione nel trattamento dell'ipertensione. http://www.agenziafarmaco.gov.it/it/content/ raccomandazioniaifa- la-terapia-di-combinazione-nel-trattamento- dell'ipertensione. Ultima consultazione: aprile 2011
40. Malacco E, Omboni S, Volpe M, et al. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. J Hypertens 2010; 28: 2342-50
41. Parati G, Ochoa JE, Ramos C, et al. Efficacy and tolerability of olmesartan/ amlodipine combination therapy in patients with mild-to-severe hypertension: focus on 24-h blood pressure control. Ther Adv Cardiovasc Dis 2010; 4: 301-13